Literature DB >> 18076610

Evaluation of the sclerotherapeutic efficacy of ethanol, polidocanol, and OK-432 using an in vitro model.

William Mol1, Hiroshi Furukawa, Satoru Sasaki, Utano Tomaru, Toshihiko Hayashi, Akira Saito, Munetomo Nagao, Noriko Saito, Shinya Hata, Yuhei Yamamoto.   

Abstract

BACKGROUND: Sclerosants are used to treat vascular malformations. Owing to variations in the flow, the injected concentrations and the duration of exposure of these sclerosants are altered. Therefore, the clinical effectiveness of sclerotherapy is variable.
OBJECTIVE: The objective was to evaluate the differences in clinical response, usually observed among ethanol, polidocanol, and OK-432, using an in vitro sclerotherapy model.
METHODS: Endothelial cells were cultured and exposed to different concentrations of the sclerosants for 5 seconds and the remaining viable cells were counted using a MTT assay kit. Dyes were used to visualize the morphologic changes. Precipitant formation in blood was also evaluated. Finally, the degree of ICAM-1 expression, after exposure to lower concentrations of these sclerosants, was studied using immunocytochemistry.
RESULTS: Only ethanol causes precipitant formation and kills almost all cells from 30% concentration. Polidocanol begins to disrupt the cell membrane from 0.0125% onward. Only OK-432 induces ICAM-1 expression.
CONCLUSION: Ethanol's strong precipitant-forming effect may induce thromboembolism, thus enhancing sclerosis. Polidocanol's endothelial cell-lysing effect was clearly documented. OK-432 may mediate its effect by inducing inflammatory response of the endothelium via ICAM-1 expression. This in vitro model may be useful in evaluating other sclerosants as well.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18076610     DOI: 10.1111/j.1524-4725.2007.33315.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  7 in total

1.  Percutaneous sclerotherapy for arteriovenous malformations of the face in the outpatient clinic.

Authors:  N Saito; S Sasaki; H Furukawa; W Mol; A Saito; Y Yamamoto
Journal:  Acta Otorhinolaryngol Ital       Date:  2010-06       Impact factor: 2.124

2.  Acquired iris inclusion cysts.

Authors:  Aruna Dharmasena; Priya Bhatt; Jeffrey Kwartz
Journal:  Int J Ophthalmol       Date:  2014-08-18       Impact factor: 1.779

3.  Polidocanol sclerotherapy for painful venous malformations: evaluation of safety and efficacy in pain relief.

Authors:  Hidefumi Mimura; Hiroyasu Fujiwara; Takao Hiraki; Hideo Gobara; Takashi Mukai; Tsuyoshi Hyodo; Toshihiro Iguchi; Kotaro Yasui; Yoshihiro Kimata; Susumu Kanazawa
Journal:  Eur Radiol       Date:  2009-05-14       Impact factor: 5.315

4.  Detrimental influences of intraluminally-administered sclerotic agents on surrounding tissues and peripheral nerves: an experimental study.

Authors:  Masahide Fujiki; Masakazu Kurita; Mine Ozaki; Hayato Kawakami; Nobuyuki Kaji; Akihiko Takushima; Kiyonori Harii
Journal:  J Plast Surg Hand Surg       Date:  2012-06-11

5.  Foam sclerotherapy for a symptomatic hepatic cyst: a preliminary report.

Authors:  Chihiro Itou; Jun Koizumi; Takeshi Hashimoto; Kazunori Myojin; Tatehiro Kagawa; Tetsuya Mine; Yutaka Imai
Journal:  Cardiovasc Intervent Radiol       Date:  2013-10-30       Impact factor: 2.740

6.  In vitro and ex vivo evaluation of the biological performance of sclerosing foams.

Authors:  Elisabetta Bottaro; Jemma A J Paterson; Luciano Quercia; Xunli Zhang; Martyn Hill; Venisha A Patel; Stephen A Jones; Andrew L Lewis; Timothy M Millar; Dario Carugo
Journal:  Sci Rep       Date:  2019-07-08       Impact factor: 4.379

7.  Polidocanol Sclerotherapy Combined with Transarterial Embolization Using n-Butyl Cyanoacrylate for Extracranial Arteriovenous Malformations.

Authors:  Akira Kitagawa; Takahiro Yamamoto; Nozomu Matsunaga; Mayako Yamaji; Shuji Ikeda; Yuichiro Izumi; Makiyo Hagihara; Toyohiro Ota; Tsuneo Ishiguchi
Journal:  Cardiovasc Intervent Radiol       Date:  2018-02-07       Impact factor: 2.740

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.